Keystone Bio, founded with a mission to combat chronic inflammation-related diseases, is a next-gen PharmaBiome biotech company. Its core vision is to pioneer novel therapeutics and diagnostics targeting Porphyromonas gingivalis (Pg), a keystone pathogen linked to systemic inflammation. Keystone Bio focuses on diagnosing, treating, and preventing inflammation-driven diseases such as atherosclerosis, heart disease, and Alzheimer's. By integrating biotechnology, medicine, and dentistry, the company aims to shut down the systemic inflammation caused by Pg.

Notable affiliated individuals and investors include leading experts in biotechnology and healthcare sectors. Keystone Bio has achieved significant milestones by identifying unique toxins released by Pg that contribute to chronic diseases. This discovery has positioned the company at the forefront of innovative treatments for inflammation-driven conditions. The impact of Keystone Bio's work is profound, offering potential breakthroughs in managing and preventing some of the most debilitating diseases affecting millions globally.